Abstract:Background Epstein Barr virus (EBV) is a highly prevalent herpesvirus worldwide and its infection is associated with malignancies such as nasopharyngeal cancer (NPC), gastric cancer, lymphoepithelioma cancer and lymphoproliferative disorders. Virus-specific T (VST) cell therapies using T cells reactive against EBV have shown limited efficacy in clinical trials with several practical limitations such as the long preparation period and the variations of pre-existing EBV-reactive T cells in different donors. To overcome these technical constraints of the VST approach, we have established the genetically engineered T cells targeting EBV antigens with lentiviral transduction. A proof-of-concept clinical validation was further conducted against EBV+ malignancies (trial No. ChiCTR2100044497). Methods T cells were activated by CD3/CD28 stimulation, lentivirally transduced with codon-optimized CAR (targeting EBV envelope protein) or TCR (targeting EBV latent membrane protein) and further expanded ex vivo. Transgene expression and the T cell phenotype were assessed by flow cytometry. In vitro anti-tumor efficacy was analyzed by IFN-γ ELISA and killing assays such as RTCA Xcelligence. In vivo, the antitumor efficacy of EBV-specific T cells was evaluated in immunocompromised mice bearing human tumor xenografts. Anti-tumor responses in lymphoma and NPC were evaluated by Lugano 2014 and RECIST 1.1 respectively. Results T cells lentivirally transduced with EBV antigen-specific CAR or TCR demonstrated satisfactory surface expression of the introduced receptor and showed increased cytokine production when stimulated to target expressing tumor cells in vitro (figure 1). We have identified the TCRs against EBV latent membrane protein with high functional avidity as determined by peptide dose-response functional assays. In vitro cytotoxicity assays demonstrated strong killing of antigen positive tumor cell lines of the engineered EBV-specific CAR-T or TCR-T cells, while sparing the antigen-negative cells, indicating the specific T cell response. The single intravenous infusion of engineered EBV-specific T cells also led to dose-dependent anti-tumor responses in immunocompromised mouse xenograft models (figure 1). In the clinical trial, two patients with lymphoproliferative disease and one patient with advanced NPC treated with engineered EBV-targeting T cells experienced sustained objective responses. Moreover, in the NPC patient, the EBV DNA copy number decreased from 3.32*103 copies/ml at baseline to normal (<5.00*102 copies/ml) 2 months post infusion. The infused cells also demonstrated satisfactory safety profile with no neurotoxicity and ≥ Grade 2 cytokine release syndrome observed. Conclusions Our data demonstrate the feasibility of using genetically engineered T cells targeting EBV antigens such as envelope protein or latent membrane protein to treat EBV-associated malignancies. Trial Registration Chinese Clinical Trial Registry: ChiCTR2100044497 Ethics Approval All animal studies were conducted at Guangzhou Regenerative Medicine and Health, Guangdong Laboratory as approved by IACUC (2020125). The clinical study was approved by the first affiliated hospital of Zhengzhou University's Ethics Board (L2021-Y027–005).

Prophylactic and Therapeutic EBV Vaccines: Major Scientific Obstacles, Historical Progress, and Future Direction

The progress of virus-targeted new therapy against Epstein-Barr virus-associated malignancies

Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases

A Frontier in EBV Vaccine Research: mRNA-Based Immunization with gp350, gp42, and gL Glycoproteins

Vesicular Stomatitis Virus-Based Epstein-Barr Virus Vaccines Elicit Strong Protective Immune Responses

Epstein‒Barr virus-associated cellular immunotherapy

An Insect Cell-Derived Extracellular Vesicle-Based Gb Vaccine Elicits Robust Adaptive Immune Responses Against Epstein-Barr Virus

Targeting the signaling in Epstein–Barr virus-associated diseases: mechanism, regulation, and clinical study

The Novel Immune Landscape of Immune-Checkpoint Blockade in EBV-associated Malignancies.

GB and gH/gL fusion machinery: a promising target for vaccines to prevent Epstein-Barr virus infection

Epigenetic Regulation of Epstein–Barr Virus: from Bench to Bedside

Epstein-Barr Viruses: Their Immune Evasion Strategies and Implications for Autoimmune Diseases

TianTan vaccinia virus-based EBV vaccines targeting both latent and lytic antigens elicits potent immunity against lethal EBV challenge in humanized mice

Anti‐EBV antibodies: Roles in diagnosis, pathogenesis, and antiviral therapy

328 Preclinical Analyses and Proof of Concept Clinical Study of Epstein Barr Virus (EBV) Specific Genetically Modified T Cells Against EBV Associated Malignancies

Safety, Tolerability, and Immunogenicity of WGc-043 in Subjects with EBV-positive Cancers: Results from an Investigator-Initiated Trial.

Treatment of Epstein-Barr Virus infection in immunocompromised patients

Immunoinformatic and systems biology approaches to predict and validate peptide vaccines against Epstein–Barr virus (EBV)

A Novel High Throughput Assay to Quantify Epstein-Barr Virus Neutralizing Antibody Activity Against B-cell and Epithelial Cell Infections for Vaccine and Therapeutic Developments.

Epstein-Barr Virus as a Promising Immunotherapeutic Target for Nasopharyngeal Carcinoma Treatment

A gB nanoparticle vaccine elicits a protective neutralizing antibody response against EBV